Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Current Assets (2023 - 2025)

Kura Oncology (KURA) has disclosed Current Assets for 3 consecutive years, with $708.7 million as the latest value for Q4 2025.

  • Quarterly Current Assets fell 4.86% to $708.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $708.7 million through Dec 2025, down 4.86% year-over-year, with the annual reading at $708.7 million for FY2025, 4.86% down from the prior year.
  • Current Assets for Q4 2025 was $708.7 million at Kura Oncology, up from $620.7 million in the prior quarter.
  • The five-year high for Current Assets was $744.8 million in Q4 2024, with the low at $416.4 million in Q1 2023.
  • Average Current Assets over 3 years is $562.8 million, with a median of $518.8 million recorded in 2024.
  • The sharpest move saw Current Assets soared 72.22% in 2024, then decreased 4.86% in 2025.
  • Over 3 years, Current Assets stood at $432.5 million in 2023, then surged by 72.22% to $744.8 million in 2024, then fell by 4.86% to $708.7 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $708.7 million, $620.7 million, and $660.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.